Last reviewed · How we verify
Compazine (PROCHLORPERAZINE)
Compazine (prochlorperazine) is a phenothiazine antipsychotic medication originally developed by GlaxoSmithKline in 1956. It works by targeting the D(2) dopamine receptor, which helps to reduce nausea and vomiting, as well as anxiety and schizophrenia symptoms. Compazine is available as a generic medication, with multiple manufacturers, and is used to treat a range of conditions including nausea and vomiting, nonpsychotic anxiety, and schizophrenia. The medication has a half-life of 9.0 hours and bioavailability of 15%. It is off-patent, meaning it is no longer protected by patents.
At a glance
| Generic name | PROCHLORPERAZINE |
|---|---|
| Sponsor | GSK |
| Drug class | Phenothiazine |
| Target | D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Nausea and vomiting
- Nonpsychotic Anxiety
- Prolonged-Severe Nausea and Vomiting
- Schizophrenia
Common side effects
- Dystonia
- Tardive dyskinesia
- Pseudo-Parkinsonism
- Motor Restlessness
- Akathisia
- Grand mal convulsions
- Petit mal convulsions
- Spasm of the neck muscles
- Tightness of the throat
- Swallowing difficulty
- Difficulty breathing
- Protrusion of the tongue
Drug interactions
- cabergoline
- entacapone
- levodopa
- pergolide
- pramipexole
- ropinirole
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines (PHASE3)
- Intranasal Ketorolac Trial (PHASE2)
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC (PHASE2)
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy (PHASE3)
- Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compazine CI brief — competitive landscape report
- Compazine updates RSS · CI watch RSS
- GSK portfolio CI